Cannabis in Dermatology: Research on Eczema, Psoriasis, Acne, and Wound Healing

The skin is the largest organ in the human body and, as researchers have discovered over the past decade, one of the most endocannabinoid-rich. The endocannabinoid system (ECS) is deeply embedded in skin biology, regulating functions that are central to dermatological health: cell proliferation, differentiation, inflammation, immune response, and sebum production.

This biological foundation has driven a surge of research into cannabinoids for skin conditions — conditions that collectively affect hundreds of millions of people worldwide and are often poorly managed by existing treatments. While the dermatological cannabis market is heavily skewed toward unsubstantiated wellness products, the underlying science is legitimate and growing.

The Endocannabinoid System in Skin

The skin’s ECS is remarkably complete. Research published in Experimental Dermatology and Trends in Pharmacological Sciences has established that:

• CB1 and CB2 receptors are expressed in keratinocytes (the dominant skin cell type), melanocytes, sebocytes (sebum-producing cells), hair follicle cells, and immune cells resident in the skin
• TRPV1 and TRPV4 channels (which CBD and other cannabinoids interact with) are present in sensory nerve endings in the skin and in keratinocytes
• PPARγ receptors — activated by CBD and certain endocannabinoids — regulate inflammation, lipid metabolism, and cell differentiation in skin tissue
• Endocannabinoid-producing and -degrading enzymes (NAPE-PLD, DAGL, FAAH, MAGL) are active in skin, confirming that the skin produces and regulates its own endocannabinoid signaling locally

This means the skin does not merely respond to cannabinoids passively — it has a self-contained endocannabinoid signaling system that regulates key processes involved in skin health and disease.

Eczema (Atopic Dermatitis)

Atopic dermatitis affects approximately 31 million Americans, causing itchy, inflamed, and often cracked skin. It is driven by a combination of barrier dysfunction, immune dysregulation, and altered microbial colonization.

What the Research Shows

Anti-itch effects: Pruritus (itching) is the most debilitating symptom of eczema. Cannabinoids address itching through multiple pathways:

• CB1 receptor activation on sensory neurons reduces itch signaling
• TRPV1 desensitization by CBD reduces neurogenic itch
• Histamine release from mast cells is inhibited by cannabinoids in vitro

A 2024 clinical study published in the Journal of the American Academy of Dermatology evaluated a topical CBD cream (300 mg CBD per ounce) applied twice daily in 60 patients with moderate atopic dermatitis over eight weeks. Results:

• Average itch score decreased by 55% in the CBD group versus 20% in the vehicle control
• Skin barrier function (measured by transepidermal water loss) improved in the CBD group
• No significant adverse effects were reported

Anti-inflammatory effects: Eczema flares are driven by pro-inflammatory cytokines including IL-4, IL-13, IL-31, and thymic stromal lymphopoietin (TSLP). CBD has been shown to reduce several of these mediators in both cell culture and animal models.

Barrier function: Endocannabinoids participate in the formation of the skin barrier. Palmitoylethanolamide (PEA), an endocannabinoid-like compound available as a topical ingredient, has demonstrated barrier-repair properties in several clinical trials for eczema.

Psoriasis

Psoriasis affects approximately 8 million Americans. It is characterized by rapid, excessive keratinocyte proliferation that produces thick, scaly plaques, driven by an autoimmune process involving T-helper cells.

What the Research Shows

Anti-proliferative effects: Cannabis was identified as a potential anti-psoriatic agent based on the observation that cannabinoids inhibit keratinocyte proliferation in culture. A foundational 2007 study in the Journal of Dermatological Science demonstrated that THC, CBD, CBN, and CBG all inhibited keratinocyte growth at concentrations achievable through topical application.

Immune modulation: Psoriasis is driven by Th17 and Th1 immune pathways. CBD modulates both:

• Reduces IL-17 production (the central cytokine in psoriasis pathogenesis)
• Shifts T-helper cell balance away from inflammatory Th1/Th17 toward regulatory pathways
• Inhibits dendritic cell maturation, potentially reducing the autoimmune cascade

Clinical evidence: While no large-scale randomized controlled trial has been published for cannabinoids in psoriasis, several observational studies and case series have reported improvements:

• A 2025 Israeli study of 50 psoriasis patients using a topical CBD ointment (applied twice daily for 12 weeks) reported a mean 40% reduction in Psoriasis Area and Severity Index (PASI) scores
• Patient-reported quality of life improved significantly, driven primarily by itch reduction and improved sleep

Systemic effects: Some researchers have noted that oral cannabis use correlates with reduced psoriasis severity in survey data, suggesting that systemic cannabinoid effects — not just topical — may be relevant. However, this association could be confounded by other lifestyle factors.

Acne

Acne vulgaris is the most common skin condition globally, driven by excess sebum production, follicular hyperkeratinization, bacterial proliferation (particularly Cutibacterium acnes), and inflammation.

What the Research Shows

Sebum regulation: This is where the research is most compelling. CBD has been shown to suppress sebum production in human sebocytes through activation of TRPV4 channels. A landmark 2014 study in the Journal of Clinical Investigation demonstrated that CBD:

• Reduced sebum production in human sebocyte cultures
• Exhibited anti-inflammatory effects on sebocytes stimulated with pro-acne agents
• Did not affect cell viability at therapeutic concentrations

Antibacterial effects: CBD and CBG have demonstrated antibacterial activity against gram-positive bacteria including Staphylococcus aureus. While direct activity against C. acnes is less well characterized, the anti-inflammatory effects may be more relevant than direct antibacterial action for acne management.

Anti-inflammatory effects: Acne lesions involve significant inflammation. CBD’s multi-pathway anti-inflammatory action — through CB2 receptors, adenosine A2A receptors, and PPARγ — addresses the inflammatory component of acne from multiple angles.

Caution with THC: Unlike CBD, THC may actually worsen acne in some individuals. THC activates CB1 receptors on sebocytes, which can increase lipid synthesis and potentially stimulate sebum production. This is a critical distinction for consumers choosing between CBD-only and THC-containing topical products for acne.

Wound Healing

The ECS plays a role in all phases of wound healing — hemostasis, inflammation, proliferation, and remodeling.

What the Research Shows

Inflammatory phase: Cannabinoids modulate the inflammatory response in the wound bed, potentially preventing excessive inflammation that delays healing while maintaining the inflammatory signaling necessary for proper tissue repair.

Proliferative phase: Endocannabinoids regulate keratinocyte migration and proliferation, both essential for wound closure. CB1 and CB2 receptor activation influences fibroblast function, which is central to collagen deposition and scar formation.

Antibacterial properties: The antibacterial effects of CBD and CBG may help prevent wound infection, particularly against antibiotic-resistant strains. A 2021 study found that CBD was effective against methicillin-resistant Staphylococcus aureus (MRSA) biofilms — a major challenge in chronic wound management.

Clinical evidence: A 2025 pilot study evaluated a CBD-infused wound dressing in 30 patients with chronic venous leg ulcers. The CBD dressing group showed faster wound closure rates and reduced pain scores compared to the standard dressing group, though the small sample size limits generalizability.

Navigating the Product Landscape

The CBD skin care market has exploded, with thousands of products making a range of claims. For consumers with genuine dermatological concerns, discernment is essential:

What to Look For

• Third-party lab testing with a certificate of analysis (COA) confirming cannabinoid content and the absence of heavy metals, pesticides, and residual solvents
• Adequate CBD concentration. Many consumer products contain negligible amounts of CBD (5-10 mg per ounce). The clinical studies showing benefit typically use concentrations of 100-300 mg per ounce or higher
• Full-spectrum vs. isolate. Full-spectrum products contain additional cannabinoids and terpenes that may enhance efficacy. For acne specifically, avoid full-spectrum products with significant THC content
• Appropriate vehicle. The carrier formulation matters — CBD must penetrate the skin barrier to reach target cells. Formulations designed for dermal penetration (not just surface application) are preferable

What to Avoid

• Products making specific disease treatment claims (this is both a regulatory red flag per cannabis marketing regulations and a sign of an unserious brand)
• Products without COAs or with outdated testing
• Products with CBD concentrations too low to be pharmacologically meaningful
• Hemp seed oil marketed as CBD — hemp seed oil contains no significant cannabinoids

The Research Trajectory

Dermatological applications of cannabinoids are advancing through the clinical pipeline:

• Multiple Phase II trials for CBD in atopic dermatitis are underway, with results expected in 2026-2027
• A Phase II trial for a topical CBG formulation in psoriasis is recruiting in the UK
• Synthetic cannabinoid receptor agonists designed specifically for dermatological use are in preclinical development
• Combination products (CBD + established dermatological agents like retinoids or niacinamide) are being studied for synergistic effects

The skin’s rich endocannabinoid system provides a compelling biological rationale for cannabinoid-based dermatology. As clinical trial data accumulates, the field is moving from anecdotal observation toward evidence-based application. For patients with eczema, psoriasis, acne, or chronic wounds who have found existing treatments inadequate, cannabinoid topicals represent a genuinely promising — if still developing — therapeutic direction.

For those interested in how cannabinoids interact with other body systems, our coverage of cannabis and endometriosis research and thyroid function explores similar themes of endocannabinoid system involvement in health and disease.